Replimune Group, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Replimune Group Inc. filed a Form 10-K detailing its capital stock, including common stock and preferred stock, and outstanding pre-funded warrants.
NASDAQ
Replimune Group outlines its capital stock composition, including common and preferred shares, pre-funded warrants, and provisions designed to deter unsolicited acquisitions in its recent 10-K filing.
NASDAQ
Replimune Group, Inc. files its annual report on Form 10-K, highlighting clinical trial progress, manufacturing updates, and strategic collaborations for its oncolytic immunotherapy pipeline.